Congress Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Congress Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,677	Closed	-$479K	–	370
2021 Q3	$479K	Sell	3,677 -61	-2%	-$9.22K	﹤0.01%	328
2021 Q2	$664K	Buy	3,738 +3	+0.1%	+$520	0.01%	311
2021 Q1	$614K	Sell	3,735 -263	-7%	-$43.3K	0.01%	312
2020 Q4	$660K	Sell	3,998 -36	-0.9%	-$5.36K	0.01%	297
2020 Q3	$575K	Sell	4,034 -2,784	-41%	-$345K	0.01%	285
2020 Q2	$752K	Sell	6,818 -544,761	-99%	-$60.2M	0.01%	268
2020 Q1	$55M	Buy	551,579 +6,052	+1%	+$782K	0.84%	65
2019 Q4	$81.4M	Buy	545,527 +5,021	+0.9%	+$683K	0.99%	47
2019 Q3	$69.3M	Buy	540,506 +8,289	+2%	+$1.11M	0.89%	58
2019 Q2	$75.9M	Sell	532,217 -2,052	-0.4%	-$276K	0.96%	50
2019 Q1	$76.4M	Buy	534,269 +64,931	+14%	+$8.47M	1%	47
2018 Q4	$58.2M	Sell	469,338 -33,685	-7%	-$5M	0.87%	55
2018 Q3	$84.6M	Sell	503,023 -3,512	-0.7%	-$604K	1.09%	41
2018 Q2	$87.3M	Buy	+506,535	New	+$82.8M	1.2%	30

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Congress Asset Management's JAZZ Position: Q4 2021 in Review

Congress Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 3,677 shares — an estimated $479K sold.

Congress Asset Management first reported a position in JAZZ in Q2 2018 and held it in 14 quarters. The position peaked at $87.3M in Q2 2018. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

Congress Asset Management reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Congress Asset Management sold 3,677 Jazz Pharmaceuticals shares in Q4 2021, an estimated $479K.
Congress Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 14 quarters.
Congress Asset Management's Jazz Pharmaceuticals position peaked at $87.3M in Q2 2018.
454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Congress Asset Management's 13F filing for Q4 2021, filed 28 Jan 2022.